Patents by Inventor Christopher John Porter

Christopher John Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LYMPH DIRECTING PRODRUGS
    Publication number: 20260151489
    Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
    Type: Application
    Filed: January 26, 2026
    Publication date: June 4, 2026
    Applicant: Monash University
    Inventors: Christopher John Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
  • Methods and compounds for treatment of metabolic disease
    Patent number: 12611415
    Abstract: The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: April 28, 2026
    Assignee: MONASH UNIVERSITY
    Inventors: Natalie Trevaskis, Christopher John Porter, Tim Quach, Sifei Han, Enyuan Cao, Luojuan Hu, Matthew Watt
  • Lipid prodrugs of JAK inhibitors and uses thereof
    Patent number: 12594339
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: April 7, 2026
    Assignees: Seaport Therapeutics, Inc., Monash University
    Inventors: Joseph Bolen, Daniel Kenneth Bonner, Ketki Karanam, Christopher John Porter, Jamie Simpson, Natalie Trevaskis, Dan Zheng, Nathania Leong, Garima Sharma, Mitchell McInerney, Tim Quach, Sifei Han
  • LYMPH DIRECTING PRODRUGS
    Publication number: 20260000769
    Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
    Type: Application
    Filed: September 8, 2025
    Publication date: January 1, 2026
    Applicant: Monash University
    Inventors: Christopher John Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
  • LYMPH DIRECTING PRODRUGS
    Publication number: 20250325671
    Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
    Type: Application
    Filed: July 3, 2025
    Publication date: October 23, 2025
    Applicant: Monash University
    Inventors: Christopher John Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
  • LYMPH DIRECTING PRODRUGS
    Publication number: 20250312461
    Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
    Type: Application
    Filed: February 13, 2025
    Publication date: October 9, 2025
    Applicant: Monash University
    Inventors: Christopher John Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
  • Tripartite Modulators of Endosomal G Protein-Coupled Receptors
    Publication number: 20250235544
    Abstract: The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.
    Type: Application
    Filed: September 3, 2024
    Publication date: July 24, 2025
    Inventors: Nigel W. Bunnett, Christopher John Porter, Derek Cole, Gareth Hicks, Junya Shirai, Gavin Hirst, Luigi Aurelio
  • LYMPH-TARGETING FORMULATIONS
    Publication number: 20250152550
    Abstract: The present invention relates to pharmaceutical formulations comprising a lipase inhibitor and long-chain fatty acids. The formulation enables the lipase inhibitor to be delivered to the intestinal lymph and are thereby useful in the treatment or prevention of diseases and conditions mediated by pancreatic lipase, such as acute pancreatitis and associated syndromes.
    Type: Application
    Filed: October 26, 2021
    Publication date: May 15, 2025
    Inventors: Natalie TREVASKIS, Christopher John PORTER, Given LEE, Sifel HAN, Anthony PHILLIPS, John WINDSOR, Jiwon HONG, Ian Kenneth STYLES, Zijun LU
  • LIPID PRODRUGS OF NEUROSTEROIDS
    Publication number: 20240245788
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
    Type: Application
    Filed: January 10, 2024
    Publication date: July 25, 2024
    Applicants: PureTech LYT, Inc., Monash University
    Inventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
  • Lipid prodrugs of neurosteroids
    Patent number: 11975073
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
    Type: Grant
    Filed: June 26, 2023
    Date of Patent: May 7, 2024
    Assignees: PureTech LYT, Inc., Monash University
    Inventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
  • LYMPH DIRECTING PRODRUGS
    Publication number: 20240050573
    Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
    Type: Application
    Filed: June 28, 2023
    Publication date: February 15, 2024
    Applicant: Monash University
    Inventors: Christopher John Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
  • LIPID PRODRUGS OF NEUROSTEROIDS
    Publication number: 20230338552
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
    Type: Application
    Filed: June 26, 2023
    Publication date: October 26, 2023
    Applicants: PureTech LYT, Inc., Monash University
    Inventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
  • Tripartite Modulators of Endosomal G Protein-Coupled Receptors
    Publication number: 20230119819
    Abstract: The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.
    Type: Application
    Filed: May 6, 2022
    Publication date: April 20, 2023
    Inventors: Nigel W. Bunnett, Christopher John Porter, Derek Cole, Gareth Hicks, Junya Shirai, Gavin Hirst, Luigi Aurelio
  • Lipid prodrugs of rapamycin and its analogs and uses thereof
    Patent number: 11608345
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: March 21, 2023
    Assignees: PureTech LYT, Inc., Monash University
    Inventors: Daniel Kenneth Bonner, Sifei Han, Luojuan Hu, Ketki Karanam, Christopher John Porter, Tim Quach, Rishab R. Shyam, Jamie Simpson, Natalie Trevaskis
  • LIPID PRODRUGS OF RAPAMYCIN AND ITS ANALOGS AND USES THEREOF
    Publication number: 20230062834
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
    Type: Application
    Filed: December 19, 2018
    Publication date: March 2, 2023
    Inventors: Daniel Kenneth BONNER, Sifei HAN, Luojuan HU, Ketki KARANAM, Christopher John PORTER, Tim QUACH, Rishab R. SHYAM, Jamie SIMPSON, Natalie TREVASKIS
  • LIPID PRODRUGS OF NEUROSTEROIDS
    Publication number: 20220395513
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
    Type: Application
    Filed: August 4, 2022
    Publication date: December 15, 2022
    Applicants: PureTech LYT, Inc., Monash University
    Inventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
  • METHODS AND COMPOUNDS FOR TREATMENT OF METABOLIC DISEASE
    Publication number: 20220339168
    Abstract: The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.
    Type: Application
    Filed: September 21, 2020
    Publication date: October 27, 2022
    Inventors: Natalie TREVASKIS, Christopher John PORTER, Tim QUACH, Sifei HAN, Enyuan CAO, Luojuan HU, Matthew WATT
  • Tripartite modulators of endosomal G protein-coupled receptors
    Patent number: 11324832
    Abstract: The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 10, 2022
    Assignee: Endosome Therapeutics, Inc.
    Inventors: Nigel W. Bunnett, Christopher John Porter, Derek Cole, Gareth Hicks, Junya Shirai, Gavin Hirst, Luigi Aurelio
  • LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF
    Publication number: 20220125933
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
    Type: Application
    Filed: February 28, 2020
    Publication date: April 28, 2022
    Inventors: Joseph BOLEN, Daniel Kenneth BONNER, Ketki KARANAM, Christopher John PORTER, Jamie SIMPSON, Natalie TREVASKIS, Dan ZHENG, Nathania LEONG, Garima SHARMA, Mitchell MCINERNEY, Tim QUACH, Sifei HAN
  • LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF
    Publication number: 20210300962
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
    Type: Application
    Filed: August 2, 2019
    Publication date: September 30, 2021
    Inventors: Daniel Kenneth BONNER, Ketki KARANAM, Jamie SIMPSON, Christopher John PORTER, Natalie TREVASKIS, Tim QUACH, Sifei HAN, Luojuan HU